Please login to the form below

Not currently logged in
Email:
Password:

Array Biopharma hires Dr Howard Holden as VP regulatory affairs

Will oversee attempts to bring to market pipeline of small molecule drugs to treat cancer and inflammatory diseases

Dr Howard Holden has joined Array Biopharma as VP of regulatory affairs and quality assurance.

Dr Holden will handle regulatory proceedings as the US biopharma aims to bring to market its pipeline of small molecule drugs to treat cancer and inflammatory diseases.

He has spent over 25 years in the pharma and biotech industry, including most recently 7 years at Nereus Pharmaceuticals as senior VP regulatory affairs and compliance.

Previously, Dr Holden was VP of regulatory affairs and compliance at Stressgen Biotechnologies and Ligand Pharmaceuticals; senior director at Parke-Davis/Warner-Lambert, director at Centocor and senior investigator at the US National Cancer Institute.

"Howard's lifetime of regulatory experience will help Array navigate the FDA approval path for our proprietary programmes," said Kyle Lefkoff, executive chair, Array BioPharma.

"He will make an immediate contribution as we move our pipeline into registration studies, and we're all excited to have Howard on the Array team."

27th April 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Langland

Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....